Researchers at the University of Pittsburgh are looking for people to join a trial for a potential Alzheimer's prevention drug.
Pitt is one of about 70 places hosting a trial of Lecanemab to determine if the drug can prevent the disease.
Candidates must be 55 to 80 years old and symptom-free, but at risk of developing Alzheimer’s.
Potential participants would undergo a scan to see if they have a specific plaque on their brains.
The four-year study could have game-changing results.